SML2305
BPK-29
≥98% (HPLC)
别名:
2-Chloro-N-[hexahydro-1-[4-(4-morpholinyl)benzoyl]-1H-azepin-4-yl]-N-(phenylmethyl)-acetamide, N-Benzyl-2-chloro-N-[1-(4-morpholin-4-yl-benzoyl)-azepan-4-yl]-acetamide
InChI
1S/C26H32ClN3O3/c27-19-25(31)30(20-21-5-2-1-3-6-21)24-7-4-13-29(14-12-24)26(32)22-8-10-23(11-9-22)28-15-17-33-18-16-28/h1-3,5-6,8-11,24H,4,7,12-20H2
InChI key
ZKWKNYRAPOSUDO-UHFFFAOYSA-N
SMILES string
O=C(CCl)N(C1CCN(C(C2=CC=C(N3CCOCC3)C=C2)=O)CCC1)CC4=CC=CC=C4
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
BPK-29 is a potent and selective NR0B1 ligand that covalently binds to NR0B1 Cys 274. BPK-29 inhibits the NR0B1-SNW1 interaction. It inhibits the anchorage-independent growth of KEAP1-mutant cancer cells.
BPK-29 is a small molecule inhibitor that blocks the nuclear factor erythroid 2–related factor 2 (NRF2) pathway. It targets the cysteine 274 residue in the nuclear receptor subfamily 0 group B member 1 (NR0B1) and disrupts protein-protein interactions in non-small-cell lung cancer (NSCLC) cell proteomes.
potent and selective NR0B1 ligand that covalently binds to NR0B1 Cys 274
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Novel Biology and Druggable Targets via Chemoproteomics.
Alan Saghatelian
Biochemistry, 56(50), 6515-6516 (2017-12-08)
Liron Bar-Peled et al.
Cell, 171(3), 696-709 (2017-10-03)
The transcription factor NRF2 is a master regulator of the cellular antioxidant response, and it is often genetically activated in non-small-cell lung cancers (NSCLCs) by, for instance, mutations in the negative regulator KEAP1. While direct pharmacological inhibition of NRF2 has
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持